Evolving Therapeutic Strategies for the Classic Philadelphia-Negative Myeloproliferative Neoplasms
Despite the emergence of JAK inhibitors, there is a need for disease-modifying treatments for Philadelphia-negative myeloproliferative neoplasms (MPNs). JAK inhibitors ameliorate symptoms and address splenomegaly, but because of the heterogeneous contributors to the disease process, JAK inhibitor mo...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2016-01-01
|
Series: | EBioMedicine |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S235239641630007X |
id |
doaj-558eab85317c4d4da095b7a683c7cc62 |
---|---|
record_format |
Article |
spelling |
doaj-558eab85317c4d4da095b7a683c7cc622020-11-25T02:48:23ZengElsevierEBioMedicine2352-39642016-01-013C172510.1016/j.ebiom.2016.01.010Evolving Therapeutic Strategies for the Classic Philadelphia-Negative Myeloproliferative NeoplasmsJason B. Kaplan0Brady L. Stein1Brandon McMahon2Francis J. Giles3Leonidas C. Platanias4Robert H. Lurie Comprehensive Cancer Center and Division of Hematology/Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL, United StatesRobert H. Lurie Comprehensive Cancer Center and Division of Hematology/Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL, United StatesRobert H. Lurie Comprehensive Cancer Center and Division of Hematology/Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL, United StatesRobert H. Lurie Comprehensive Cancer Center and Division of Hematology/Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL, United StatesRobert H. Lurie Comprehensive Cancer Center and Division of Hematology/Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL, United StatesDespite the emergence of JAK inhibitors, there is a need for disease-modifying treatments for Philadelphia-negative myeloproliferative neoplasms (MPNs). JAK inhibitors ameliorate symptoms and address splenomegaly, but because of the heterogeneous contributors to the disease process, JAK inhibitor monotherapy incompletely addresses the burden of disease. The ever-growing understanding of MPN pathogenesis has provided the rationale for testing novel and targeted therapeutic agents, as monotherapies or in combination, in preclinical and clinical settings. A number of intriguing options have emerged, and it is hoped that further progress will lead to significant changes in the natural history of MPNs.http://www.sciencedirect.com/science/article/pii/S235239641630007XMyeloproliferative neoplasmMyelofibrosisTherapyTargetedNovelCombination |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Jason B. Kaplan Brady L. Stein Brandon McMahon Francis J. Giles Leonidas C. Platanias |
spellingShingle |
Jason B. Kaplan Brady L. Stein Brandon McMahon Francis J. Giles Leonidas C. Platanias Evolving Therapeutic Strategies for the Classic Philadelphia-Negative Myeloproliferative Neoplasms EBioMedicine Myeloproliferative neoplasm Myelofibrosis Therapy Targeted Novel Combination |
author_facet |
Jason B. Kaplan Brady L. Stein Brandon McMahon Francis J. Giles Leonidas C. Platanias |
author_sort |
Jason B. Kaplan |
title |
Evolving Therapeutic Strategies for the Classic Philadelphia-Negative Myeloproliferative Neoplasms |
title_short |
Evolving Therapeutic Strategies for the Classic Philadelphia-Negative Myeloproliferative Neoplasms |
title_full |
Evolving Therapeutic Strategies for the Classic Philadelphia-Negative Myeloproliferative Neoplasms |
title_fullStr |
Evolving Therapeutic Strategies for the Classic Philadelphia-Negative Myeloproliferative Neoplasms |
title_full_unstemmed |
Evolving Therapeutic Strategies for the Classic Philadelphia-Negative Myeloproliferative Neoplasms |
title_sort |
evolving therapeutic strategies for the classic philadelphia-negative myeloproliferative neoplasms |
publisher |
Elsevier |
series |
EBioMedicine |
issn |
2352-3964 |
publishDate |
2016-01-01 |
description |
Despite the emergence of JAK inhibitors, there is a need for disease-modifying treatments for Philadelphia-negative myeloproliferative neoplasms (MPNs). JAK inhibitors ameliorate symptoms and address splenomegaly, but because of the heterogeneous contributors to the disease process, JAK inhibitor monotherapy incompletely addresses the burden of disease. The ever-growing understanding of MPN pathogenesis has provided the rationale for testing novel and targeted therapeutic agents, as monotherapies or in combination, in preclinical and clinical settings. A number of intriguing options have emerged, and it is hoped that further progress will lead to significant changes in the natural history of MPNs. |
topic |
Myeloproliferative neoplasm Myelofibrosis Therapy Targeted Novel Combination |
url |
http://www.sciencedirect.com/science/article/pii/S235239641630007X |
work_keys_str_mv |
AT jasonbkaplan evolvingtherapeuticstrategiesfortheclassicphiladelphianegativemyeloproliferativeneoplasms AT bradylstein evolvingtherapeuticstrategiesfortheclassicphiladelphianegativemyeloproliferativeneoplasms AT brandonmcmahon evolvingtherapeuticstrategiesfortheclassicphiladelphianegativemyeloproliferativeneoplasms AT francisjgiles evolvingtherapeuticstrategiesfortheclassicphiladelphianegativemyeloproliferativeneoplasms AT leonidascplatanias evolvingtherapeuticstrategiesfortheclassicphiladelphianegativemyeloproliferativeneoplasms |
_version_ |
1724748213740634112 |